Plus therapeutics, inc. (CYTX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows used in operating activities:
Net loss

-10,887

-12,634

-22,686

-22,046

-18,744

-37,368

-26,177

-32,279

-32,451

-27,494

-23,216

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

896

2,004

2,151

1,182

1,093

779

1,630

933

855

931

1,681

Amortization of deferred financing costs and debt discount

550

578

707

954

979

1,220

893

930

711

703

709

Noncash lease expenses

12

0

-

-

-

-

-

-

-

-

-

In process research and development acquired from Azaya Therapeutics

-

-

1,686

-

-

-

-

-

-

-

-

Provision for expired inventory

-

-

-

172

0

-

-

-

-

-

-

Change in fair value of warrants

-3,407

-2,233

0

-

-7,668

-

-

-

-

-

-

Allocation of issuance cost associated with warrants

1,233

470

0

-

-

-

-

-

-

-

-

Joint venture acquisition obligation accretion

-

-

-

-

-

-579

-204

0

-

-

-

Provision for expired enzyme

-

-

-

-

-

313

0

0

-

-

-

Change in fair value of warrants

-

-

-

-

-

-369

-418

-209

-4,360

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

4,574

Change in fair value of warrants

-

-

-

-

-

0

-2,250

340

740

30

-920

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-1,285

-

Share-based compensation expense

127

355

753

1,080

2,041

3,101

3,608

3,904

3,316

3,055

2,649

Loss on sale of business

-6,508

0

-

-

-

-

-

-

-

-

-

Equity loss from investment in joint venture

-

-

-

-

-

0

-48

-165

-209

-151

-44

Loss on asset disposal

0

-36

42

127

-8

33

-257

0

-

-

-

Joint venture acquisition obligation accretion

-

-

-

24

365

-

-

-

-

-

-

Warranty provision (reversal)

-

-

-

-

-

-

-

-

-

-

-23

Provision for doubtful accounts

0

18

0

-

-105

1,084

1,141

144

483

460

663

Provision for excess inventory

0

463

340

-

-

-

-

-

-

-

-

Loss on asset disposal

-

-

-

-

-

-

-

-

0

-

-

Gain on previously held equity interest in joint venture

-

-

-

-

-

0

4,892

0

0

-

-

Gain on sale of assets

-

-

-

-

-

0

4,453

0

0

-

-

Loss on debt extinguishment

-

-

-

-

-260

0

-708

0

0

-

-

Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable

1,203

173

-1,129

179

-328

-2,057

1,209

1,810

670

902

986

Inventories

-259

-475

-251

-471

-490

815

459

-143

-60

777

446

Other current assets

211

-85

593

-633

637

-510

24

324

3

-36

-

Other assets

-263

-23

94

764

-363

-11

854

74

1,206

110

-

Other current assets

-

-

-

-

-

-

-

-

-

-

-41

Other assets

-

-

-

-

-

-

-

-

-

-

-75

Accounts payable and accrued expenses

-28

-1,532

-1,817

-673

1,045

-1,147

-409

1,183

-1,436

811

413

Deferred revenues

29

73

-3

-

-

-

-

-

-

-

-

Other long-term liabilities

-47

17

-

-

-

-

-

-

-

-

-

Long-term deferred rent and other

-

-

90

-

-

-

-

-

-

-

-

Deferred revenues, related party

-

-

-

-

-

0

-638

-2,882

-1,992

-2,122

8,840

Deferred revenues

-

-

-

-8

3

-100

-1,223

-2,609

315

2,541

-

Long-term deferred rent

-

-

-

-252

-289

-152

-46

252

106

-

-

Net cash used in operating activities

-

-

-

-19,533

-20,468

-30,330

-34,563

-32,193

-

-

-

Long-term deferred rent

-

-

-

-

-

-

-

-

-

398

-

Deferred revenues

-

-

-

-

-

-

-

-

-

-

57

Long-term deferred rent

-

-

-

-

-

-

-

-

-

-

168

Net cash used in operating activities

-5,906

-11,975

-18,128

-

-

-

-

-

-35,323

-23,574

-23,807

Cash flows used in investing activities:
Purchases of property and equipment

67

133

-

67

611

764

519

1,204

560

610

221

Proceeds from sale of business

5,637

0

-

-

-

-

-

-

-

-

-

Expenditures for intellectual property

-

-

-

-

13

255

0

0

-

-

-

Proceeds from sale of assets

-

-

113

131

11

76

5,000

0

-

-

-

Proceeds from long-term obligations

-

-

-

-

17,700

0

27,000

0

9,444

20,000

0

Debt issuance costs and loan fees

-

-

-

-

1,854

0

1,744

0

719

559

0

Cash invested in restricted cash

-

-

-

-

-

-

-

-

-

350

0

Change in restricted cash

-

-

-

0

-

-

-

-

-

-

-

Proceeds from Puregraft divestiture

-

-

-

-

-

-

-

-

0

-

-

License agreement termination fee

-

-

-

-

-

400

800

0

-

-

-

Cash acquired in purchase of the Joint Venture

-

-

-

-

-

0

5

0

0

-

-

Net cash used in investing activities

-

-

-

64

-613

-1,343

3,686

-

-

-

-

Net cash used in investing activities

5,570

-133

-1,383

-

-

-

-

-1,204

-560

-1,290

-221

Cash flows (used in) provided by financing activities:
Principal payments of long-term obligations

3,692

0

4,720

0

25,032

1,962

22,304

2,692

4,529

5,454

2,053

Payment of financing lease liability

131

0

-

-

-

-

-

-

-

-

-

Proceeds from sale of common and preferred stock

-

-

23,613

-

-

-

-

-

-

-

-

Joint venture purchase payments

-

-

-

1,774

1,623

2,262

221

0

0

330

0

Proceeds from exercise of employee stock options and warrants

-

-

-

-

4,997

4,151

225

1,413

2,849

7,128

-

Proceeds from exercise of employee stock options and warrants

-

-

-

-

-

-

-

-

-

-

531

Proceeds from sale of common stock, net

15,964

0

-

21,467

29,054

19,001

18,000

24,953

13,286

45,486

23,196

Proceeds from exercise of warrants

490

0

-

-

-

-

-

-

-

-

-

Proceeds from sale of common and preferred stock

0

7,234

-

-

-

-

-

-

-

-

-

Financial capital expenditures

0

66

0

-

-

-

-

-

-

-

-

Proceeds from issuance of preferred stock

-

-

-

-

-

13,500

0

0

-

-

-

Costs from sale of common stock

-

-

-

2,084

2,370

425

184

1,482

194

1,923

1,336

Costs from sale of common and preferred stock

-

-

2,078

-

-

1,129

0

0

-

-

-

Dividends paid on preferred stock

-

-

-

-

75

0

0

-

-

-

-

Net cash used in financing activities

-

-

-

17,609

20,797

30,874

20,772

22,192

-

-

-

Proceeds from sale of treasury stock

-

-

-

-

-

-

-

-

-

-

3,933

Net cash (used in) provided by financing activities

12,631

7,168

16,815

-

-

-

-

-

20,137

64,678

24,271

Effect of exchange rate changes on cash and cash equivalents

-4

16

11

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

12,291

-4,924

-2,685

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

82

0

-85

-106

0

0

-

-

Net decrease in cash and cash equivalents

-

-

-

-1,778

-284

-884

-10,211

-11,205

-15,746

39,814

243

Supplemental disclosure of cash flows information:
Cash paid during period for:
Interest

1,188

1,331

1,364

-

-

-

-

-

-

-

-

Interest

-

-

-

1,618

1,994

2,588

2,252

2,497

2,031

1,226

739

Final payment fee on long-term debt

-

-

-

-

1,839

0

1,078

0

419

205

0

Supplemental schedule of non-cash investing and financing activities:
Proceeds from sales of business, net, paid directly to lender for principal payment of long-term obligations

3,050

0

-

-

-

-

-

-

-

-

-

Offering cost paid in warrants

213

0

-

-

-

-

-

-

-

-

-

Reclass of warrants upon exercise from liability to equity

794

0

-

-

-

-

-

-

-

-

-

Fair value of Convertible Preferred Stock beneficial conversion feature

554

2,487

3,977

0

-

-

-

-

-

-

-

Issuance costs paid in common stock

-

-

-

189

0

-

-

-

-

-

-

Conversion of preferred stock into common

0

8

23

0

10

16

0

0

-

-

-

Declared dividend related to preferred stock

-

-

-

-

3

72

0

0

-

-

-

Fair value of warrants allocated to additional paid-in capital

-

-

-

-

776

-

-

-

-

-

-

Fair value of warrants allocated to additional paid-in capital

-

-

-

-

-

0

949

0

267

279

0

Capital equipment lease

-

-

-

-

-

-

-

-

79

0

0

Fair value of intangible assets acquired

-

-

-

-

-

0

9,394

0

0

-

-

Fair value of tangible assets acquired

-

-

-

-

-

0

260

0

0

-

-

Joint venture purchase obligation

-

-

-

-

-

0

4,709

0

0

-

-

Fair value of previously held equity interest at acquisition date

-

-

-

-

-

0

4,928

0

0

-

-

Net increase in purchases of property and equipment included in accounts payable

-

-

-

-

-

-

-

-

-

481

0

Property Plant And Equipment Excluding Research Lab Equipment And Leasehold Improvements [Member]
Purchases of property and equipment /long-lived assets

-

-

295

-

-

-

-

-

-

-

-

Assets Purchased from Azaya Therapeutics, Inc. [Member]
Purchases of property and equipment /long-lived assets

-

-

1,201

-

-

-

-

-

-

-

-

Common stock issued in payment for the assets acquired

-

-

2,311

-

-

-

-

-

-

-

-